BIOGRAPHENE is a biotech startup dedicated to developing novel graphene-based drugs for neurodegenerative diseases. Our primary targets include Parkinson's disease, Alzheimer's disease, and Niemann-Pick disease type C (NPC). We are a spin-off company from Seoul National University and incorporated as a legal entity in the state of California starting in June 2020.
